Market Overview:
The global Interleukin 1 Receptor Associated Kinase 4 market is expected to grow at a CAGR of xx% during the forecast period from 2018 to 2030. The growth in the market can be attributed to factors such as rising prevalence of autoimmune diseases, increasing R&D investments for novel therapies, and growing awareness about IL-1Ra4 inhibitors. However, the high cost of treatment and lack of reimbursement policies are restraining the growth of this market. The global Interleukin 1 Receptor Associated Kinase 4 market is segmented on the basis of type, application, and region. On the basis of type, it is divided into CA-4948, ND-2110 R-191 Others). On the basis on application it is classified into Gouty Arthritis Pasoriasis Acute Myelocytic Leukemia Others). Geographically, it is analyzed across North America Latin America Europe Asia Pacific Middle East & Africa ).
Product Definition:
Interleukin 1 receptor associated kinase 4 (IRAK4) is a protein that in humans is encoded by the IRAK4 gene. IRAK4 is a member of the interleukin-1 receptor-associated kinases (IRAKs) family. IRAK4 plays an important role in innate immunity, specifically in the activation of nuclear factor kappa B (NF-κB).
CA-4948:
CA-4948 is a selective inhibitor of IKK4. It has been shown to have IC50 values of 19 nM and 13 nM for human IL-1 receptor and human TNFRSF gene respectively. CA-4948 was developed by Calbiochem as an analog of 4947 that is used as a tool in the study of signal transduction pathways by inhibiting kinases at unique cysteine residues.
ND-2110:
Interleukin 1 receptor-associated kinase 4 (IL1RAPK4) is a protein that in humans is encoded by the IL1RAPK4 gene. The interleukin 1 receptor-associated kinase 4 market has been witnessing significant growth over the past few years on account of rising demand for therapeutics targeting type I diabetes mellitus.
Application Insights:
The global market is segmented by application into gouty arthritis, pasoriasis, acute myelocytic leukemia, and others. The gouty arthritis segment dominated the overall market in terms of revenue in 2017. This can be attributed to the rising prevalence of this disease coupled with a high treatment rate associated with this condition. Acute myelocytic leukemia (AML) is anticipated to be one of the fastest growing segments over the forecast period owing to increasing incidence rates and availability of advanced therapies for treating this condition.
Pasoriasis was estimated as one of the fastest-growing segments due to its increasing prevalence coupled with an increase in product penetration for Pasienzyme treatment worldwide since 2014.
Regional Analysis:
North America dominated the global market in 2017. The presence of a substantial number of biotechnology and pharmaceutical companies, favorable government initiatives, and high healthcare expenditure are some factors driving the regional market. For instance, in May 2018, Parexel performed a clinical trial on interleukin-1 receptor associated kinase 4 (IK4) test for acute myelocytic leukemia (AML). This was to evaluate whether IK4 testing can be used as an alternative or additional tool for making treatment decisions in patients with AML.
Asia Pacific is expected to witness lucrative growth over the forecast period owing to rising disposable income leading to increased demand for healthcare services resulting from increasing prevalence of gouty arthritis (GA), psoriasis vulgaris (PsV), acute myelocytic leukemia(AMC) & others.
Growth Factors:
- Increasing prevalence of chronic diseases: The incidence of chronic diseases is increasing at an alarming rate across the globe. This is primarily attributed to the changing lifestyle and dietary habits of people. IL-1RAK4 has been found to play a significant role in the pathogenesis of various chronic diseases, including rheumatoid arthritis, psoriasis, and Crohn’s disease. This is expected to drive the demand for IL-1RAK4 inhibitors in the coming years.
- Growing awareness about autoimmune disorders: There is a growing awareness among people about autoimmune disorders and their treatment options. This is likely to boost demand for IL-1RAK4 inhibitors in the near future as they are effective in treating such disorders.
- Technological advancements: The pharmaceutical industry is witnessing rapid advancements in technology, which are helping researchers develop novel therapeutics for various diseases, including autoimmune disorders mediated by IL-1RAK4 inhibition therapy .This will help fuel growth of the Interleukin 1 Receptor Associated Kinase 4 market over the forecast period .
Scope Of The Report
Report Attributes
Report Details
Report Title
Interleukin 1 Receptor Associated Kinase 4 Market Research Report
By Type
CA-4948, ND-2110, R-191, Others
By Application
Gouty Arthritis, Pasoriasis, Acute Myelocytic Leukemia, Others
By Companies
Amgen Inc, Astellas Pharma Inc, Aurigene Discovery Technologies Ltd, Beijing Hanmi Pharmaceutical Co Ltd, Genentech Inc, Merck & Co Inc, Rigel Pharmaceuticals Inc, TG Therapeutics Inc
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
177
Number of Tables & Figures
124
Customization Available
Yes, the report can be customized as per your need.
Global Interleukin 1 Receptor Associated Kinase 4 Market Report Segments:
The global Interleukin 1 Receptor Associated Kinase 4 market is segmented on the basis of:
Types
CA-4948, ND-2110, R-191, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Gouty Arthritis, Pasoriasis, Acute Myelocytic Leukemia, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Amgen Inc
- Astellas Pharma Inc
- Aurigene Discovery Technologies Ltd
- Beijing Hanmi Pharmaceutical Co Ltd
- Genentech Inc
- Merck & Co Inc
- Rigel Pharmaceuticals Inc
- TG Therapeutics Inc
Highlights of The Interleukin 1 Receptor Associated Kinase 4 Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- CA-4948
- ND-2110
- R-191
- Others
- By Application:
- Gouty Arthritis
- Pasoriasis
- Acute Myelocytic Leukemia
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Interleukin 1 Receptor Associated Kinase 4 Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
IL-1 receptor associated kinase 4 (IRAK4) is a protein that in humans is encoded by the IRAK4 gene. IRAK4 is a member of the IL-1 receptor family and plays an important role in mediating inflammatory responses.
Some of the major players in the interleukin 1 receptor associated kinase 4 market are Amgen Inc, Astellas Pharma Inc, Aurigene Discovery Technologies Ltd, Beijing Hanmi Pharmaceutical Co Ltd, Genentech Inc, Merck & Co Inc, Rigel Pharmaceuticals Inc, TG Therapeutics Inc.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Interleukin 1 Receptor Associated Kinase 4 Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Interleukin 1 Receptor Associated Kinase 4 Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Interleukin 1 Receptor Associated Kinase 4 Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Interleukin 1 Receptor Associated Kinase 4 Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Interleukin 1 Receptor Associated Kinase 4 Market Size & Forecast, 2020-2028
4.5.1 Interleukin 1 Receptor Associated Kinase 4 Market Size and Y-o-Y Growth
4.5.2 Interleukin 1 Receptor Associated Kinase 4 Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 CA-4948
5.2.2 ND-2110
5.2.3 R-191
5.2.4 Others
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Gouty Arthritis
6.2.2 Pasoriasis
6.2.3 Acute Myelocytic Leukemia
6.2.4 Others
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Interleukin 1 Receptor Associated Kinase 4 Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Interleukin 1 Receptor Associated Kinase 4 Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 CA-4948
9.6.2 ND-2110
9.6.3 R-191
9.6.4 Others
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Gouty Arthritis
9.10.2 Pasoriasis
9.10.3 Acute Myelocytic Leukemia
9.10.4 Others
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 CA-4948
10.6.2 ND-2110
10.6.3 R-191
10.6.4 Others
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Gouty Arthritis
10.10.2 Pasoriasis
10.10.3 Acute Myelocytic Leukemia
10.10.4 Others
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 CA-4948
11.6.2 ND-2110
11.6.3 R-191
11.6.4 Others
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Gouty Arthritis
11.10.2 Pasoriasis
11.10.3 Acute Myelocytic Leukemia
11.10.4 Others
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 CA-4948
12.6.2 ND-2110
12.6.3 R-191
12.6.4 Others
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Gouty Arthritis
12.10.2 Pasoriasis
12.10.3 Acute Myelocytic Leukemia
12.10.4 Others
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 CA-4948
13.6.2 ND-2110
13.6.3 R-191
13.6.4 Others
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Gouty Arthritis
13.10.2 Pasoriasis
13.10.3 Acute Myelocytic Leukemia
13.10.4 Others
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Interleukin 1 Receptor Associated Kinase 4 Market: Competitive Dashboard
14.2 Global Interleukin 1 Receptor Associated Kinase 4 Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Amgen Inc
14.3.2 Astellas Pharma Inc
14.3.3 Aurigene Discovery Technologies Ltd
14.3.4 Beijing Hanmi Pharmaceutical Co Ltd
14.3.5 Genentech Inc
14.3.6 Merck & Co Inc
14.3.7 Rigel Pharmaceuticals Inc
14.3.8 TG Therapeutics Inc
